MX361925B - Medicamento inhalable que comprende tiotropio. - Google Patents
Medicamento inhalable que comprende tiotropio.Info
- Publication number
- MX361925B MX361925B MX2014007357A MX2014007357A MX361925B MX 361925 B MX361925 B MX 361925B MX 2014007357 A MX2014007357 A MX 2014007357A MX 2014007357 A MX2014007357 A MX 2014007357A MX 361925 B MX361925 B MX 361925B
- Authority
- MX
- Mexico
- Prior art keywords
- tiotropium
- formulation
- inhalable medicament
- percentages
- mdi
- Prior art date
Links
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940110309 tiotropium Drugs 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta invención se refiere a una formulación para solución que comprende una sal de tiotropio, 12-20% de etanol, 0.1-1.5% de agua, 0.05-0.10% de ácido cítrico (u otro ácido orgánico) y un propelente de HFA, en donde los porcentajes son porcentajes en peso basados en el peso total de la formulación. La invención también provee un pMDI que comprende un envase que contiene la formulación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161577315P | 2011-12-19 | 2011-12-19 | |
| GBGB1200525.2A GB201200525D0 (en) | 2011-12-19 | 2012-01-13 | An inhalable medicament |
| PCT/EP2012/074690 WO2013092237A1 (en) | 2011-12-19 | 2012-12-06 | An inhalable medicament comprising tiotropium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014007357A MX2014007357A (es) | 2014-08-21 |
| MX361925B true MX361925B (es) | 2018-12-19 |
Family
ID=45813952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007357A MX361925B (es) | 2011-12-19 | 2012-12-06 | Medicamento inhalable que comprende tiotropio. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9655969B2 (es) |
| EP (3) | EP3143998B1 (es) |
| JP (1) | JP5791166B2 (es) |
| KR (2) | KR101670564B1 (es) |
| CN (1) | CN103998039A (es) |
| AR (1) | AR089302A1 (es) |
| AU (1) | AU2012358475B2 (es) |
| BR (1) | BR112014014535A2 (es) |
| CA (1) | CA2856047C (es) |
| CY (1) | CY1116142T1 (es) |
| DK (3) | DK3143998T3 (es) |
| EA (1) | EA028461B1 (es) |
| ES (3) | ES2602314T3 (es) |
| GB (1) | GB201200525D0 (es) |
| HK (2) | HK1198512A1 (es) |
| HR (1) | HRP20141176T1 (es) |
| HU (2) | HUE030983T2 (es) |
| IL (1) | IL232946A0 (es) |
| MX (1) | MX361925B (es) |
| PL (3) | PL3143998T3 (es) |
| PT (1) | PT2606891E (es) |
| RS (1) | RS53783B1 (es) |
| SI (1) | SI2606891T1 (es) |
| SM (1) | SMT201400192B (es) |
| TR (1) | TR201908429T4 (es) |
| TW (1) | TWI468187B (es) |
| UY (1) | UY34525A (es) |
| WO (1) | WO2013092237A1 (es) |
| ZA (2) | ZA201403041B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG181870A1 (en) | 2009-12-23 | 2012-07-30 | Chiesi Farma Spa | Aerosol formulation for copd |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| WO2013127738A1 (de) | 2012-02-28 | 2013-09-06 | Boehringer Ingelheim International Gmbh | Neue treibgashaltige tiotropium-formulierung |
| HUE036748T2 (hu) | 2013-11-22 | 2018-07-30 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalálható gyógyszer |
| HUE045868T2 (hu) * | 2013-11-22 | 2020-01-28 | Teva Branded Pharmaceutical Products R&D Inc | Inhalálható gyógykészítmény |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| EP3368083A1 (en) * | 2015-10-29 | 2018-09-05 | 3M Innovative Properties Company | Formulation and aerosol canisters, inhalers, and the like containing the formulation |
| CN109789131B (zh) * | 2016-09-19 | 2022-08-26 | 墨西哥氟石股份公司 | 药物组合物 |
| WO2020006017A1 (en) | 2018-06-27 | 2020-01-02 | 3M Innovative Properties Company | Tiotropium formulation and inhaler |
| WO2023039103A1 (en) * | 2021-09-08 | 2023-03-16 | Kindeva Drug Delivery L.P. | Metered dose inhalers and suspension compositions |
| US12558314B1 (en) | 2024-08-26 | 2026-02-24 | Glenmark Specialty S.A. | Pressurized inhalation composition of tiotropium |
| WO2026047392A1 (en) | 2024-08-26 | 2026-03-05 | Glenmark Specialty S.A. | A pressurized inhalation composition of tiotropium |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| GB9026191D0 (en) | 1990-12-01 | 1991-01-16 | Harris Pharma Ltd | Breath actuated dispensing device |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| NZ246046A (en) | 1991-12-12 | 1995-12-21 | Glaxo Group Ltd | Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent |
| GB2264238A (en) | 1992-05-29 | 1993-08-25 | Norton Healthcare Ltd | Medicament inhalor device |
| ES2129117T3 (es) * | 1992-12-09 | 1999-06-01 | Boehringer Ingelheim Pharma | Formulaciones en disolucion en forma de aerosol medicinales estabilizadas. |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| CN1150895C (zh) | 1998-11-13 | 2004-05-26 | 杰格研究股份公司 | 用于吸入给药的干粉 |
| DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| AU7685200A (en) | 1999-10-12 | 2001-04-23 | Kaken Pharmaceutical Co., Ltd. | Powdery inhalational preparations and process for producing the same |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| EE05167B1 (et) | 2000-05-22 | 2009-06-15 | Chiesi Farmaceutici S.P.A. | Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele |
| US6553988B1 (en) | 2000-06-09 | 2003-04-29 | Norton Healthcare, Inc. | Medicament dispensing device with a multimaterial diaphragm bounding a pneumatic force chamber |
| US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| AU2002214996B2 (en) | 2000-10-12 | 2007-03-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| AP1712A (en) | 2000-10-12 | 2007-01-24 | Boehringer Ingelheim Pharma | Novel tiotropium-containing inhalation powder |
| DE60100055T2 (de) * | 2001-03-21 | 2003-07-24 | Schwarz Pharma Ag | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
| DE10126924A1 (de) | 2001-06-01 | 2002-12-05 | Boehringer Ingelheim Pharma | Inhalationskapseln |
| US20030070679A1 (en) | 2001-06-01 | 2003-04-17 | Boehringer Ingelheim Pharma Kg | Capsules containing inhalable tiotropium |
| CA2450961C (en) | 2001-06-22 | 2010-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
| US6608055B2 (en) | 2001-06-22 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
| DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
| DE10212264A1 (de) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| US7309707B2 (en) | 2002-03-20 | 2007-12-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
| DE10214263A1 (de) | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum |
| US7311894B2 (en) | 2002-03-28 | 2007-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations containing an anticholinergic |
| GB0219511D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| US20050058606A1 (en) | 2002-12-16 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing HFC solution formulations |
| AU2003303029A1 (en) * | 2002-12-16 | 2004-07-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing hfc solution formulations |
| DE10339197A1 (de) | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| EP1699435A4 (en) | 2003-09-18 | 2009-05-20 | Norton Healthcare Ltd | PARTICLE |
| WO2005042527A1 (de) | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Neues kristallines anhydrat mit anticholinerger wirksamkeit |
| US7968717B2 (en) | 2003-11-03 | 2011-06-28 | Boehringer Ingelhein International Gmbh | Crystalline anhydrate with anticholinergic efficacy |
| SE0303570L (sv) | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
| US7914771B2 (en) | 2004-03-09 | 2011-03-29 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
| US20060079544A1 (en) | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| SG159550A1 (en) * | 2005-02-25 | 2010-03-30 | Chiesi Farma Spa | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent |
| KR20080012932A (ko) | 2005-05-02 | 2008-02-12 | 베링거 인겔하임 인터내셔날 게엠베하 | 티오트로퓸 브로마이드의 신규한 결정형 |
| EP1879888A2 (en) | 2005-05-02 | 2008-01-23 | Boehringer Ingelheim International GmbH | Crystalline forms of tiotropium bromide |
| KR20080024532A (ko) | 2005-06-15 | 2008-03-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 신규한 티오트로퓸 염의 제조방법, 신규한 티오트로퓸 염및 이의 약제학적 조성물 |
| KR20080039974A (ko) | 2005-08-06 | 2008-05-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 중증 지속성 천식의 치료에서 티오트로퓸 염의 용도 |
| TWI389692B (zh) | 2005-10-10 | 2013-03-21 | Boehringer Ingelheim Int | 用以吸入β-共效劑的氣溶膠調配物 |
| PT1869035E (pt) | 2005-12-19 | 2013-01-10 | Sicor Inc | Novas formas de brometo de tiotrópio e processos para sua preparação |
| EP1923393A1 (en) | 2006-11-17 | 2008-05-21 | Boehringer Ingelheim Pharma GmbH & Co. KG | Crystalline form of tiotropium bromide and urea |
| GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| EP2201934A1 (en) | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Tiotropium aerosol formulation products with improved chemical stability |
| CA2750711C (en) | 2009-01-26 | 2015-07-07 | Teva Pharmaceutical Industries Ltd. | Processes for coating a carrier with microparticles |
| MX2012005711A (es) * | 2009-11-17 | 2012-10-05 | Cipla Ltd | Soluciones de inhalacion. |
| SI2627386T1 (sl) | 2010-10-12 | 2015-10-30 | Ivax Pharmaceuticals Ireland | Nosna pršilna naprava |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| GB201200504D0 (en) | 2011-12-19 | 2012-02-22 | Teva Branded Pharmaceutical Prod R & D Inc | An inhaler |
| WO2013127738A1 (de) | 2012-02-28 | 2013-09-06 | Boehringer Ingelheim International Gmbh | Neue treibgashaltige tiotropium-formulierung |
-
2012
- 2012-01-13 GB GBGB1200525.2A patent/GB201200525D0/en not_active Ceased
- 2012-12-06 HK HK14111996.5A patent/HK1198512A1/xx unknown
- 2012-12-06 BR BR112014014535A patent/BR112014014535A2/pt not_active Application Discontinuation
- 2012-12-06 PL PL16185402T patent/PL3143998T3/pl unknown
- 2012-12-06 MX MX2014007357A patent/MX361925B/es active IP Right Grant
- 2012-12-06 TR TR2019/08429T patent/TR201908429T4/tr unknown
- 2012-12-06 KR KR1020147017716A patent/KR101670564B1/ko not_active Expired - Fee Related
- 2012-12-06 EA EA201491206A patent/EA028461B1/ru not_active IP Right Cessation
- 2012-12-06 DK DK16185402.1T patent/DK3143998T3/da active
- 2012-12-06 AU AU2012358475A patent/AU2012358475B2/en not_active Ceased
- 2012-12-06 HU HUE12806382A patent/HUE030983T2/en unknown
- 2012-12-06 PL PL12806382T patent/PL2793886T3/pl unknown
- 2012-12-06 KR KR1020167025194A patent/KR20160111539A/ko not_active Withdrawn
- 2012-12-06 CA CA2856047A patent/CA2856047C/en not_active Expired - Fee Related
- 2012-12-06 ES ES12806382.3T patent/ES2602314T3/es active Active
- 2012-12-06 EP EP16185402.1A patent/EP3143998B1/en not_active Revoked
- 2012-12-06 HU HUE16185402 patent/HUE044647T2/hu unknown
- 2012-12-06 US US14/367,031 patent/US9655969B2/en active Active
- 2012-12-06 ES ES16185402T patent/ES2728940T3/es active Active
- 2012-12-06 EP EP12806382.3A patent/EP2793886B1/en not_active Revoked
- 2012-12-06 DK DK12806382.3T patent/DK2793886T3/en active
- 2012-12-06 CN CN201280060763.4A patent/CN103998039A/zh active Pending
- 2012-12-06 WO PCT/EP2012/074690 patent/WO2013092237A1/en not_active Ceased
- 2012-12-06 JP JP2014543943A patent/JP5791166B2/ja not_active Expired - Fee Related
- 2012-12-06 HK HK15100893.1A patent/HK1200343A1/xx unknown
- 2012-12-12 ES ES12196725.1T patent/ES2526685T3/es active Active
- 2012-12-12 EP EP12196725.1A patent/EP2606891B1/en not_active Revoked
- 2012-12-12 PL PL12196725T patent/PL2606891T3/pl unknown
- 2012-12-12 SI SI201230113T patent/SI2606891T1/sl unknown
- 2012-12-12 PT PT121967251T patent/PT2606891E/pt unknown
- 2012-12-12 DK DK12196725.1T patent/DK2606891T3/en active
- 2012-12-12 RS RS20140691A patent/RS53783B1/sr unknown
- 2012-12-18 AR ARP120104795A patent/AR089302A1/es not_active Application Discontinuation
- 2012-12-18 UY UY0001034525A patent/UY34525A/es not_active Application Discontinuation
- 2012-12-19 TW TW101148516A patent/TWI468187B/zh not_active IP Right Cessation
-
2014
- 2014-04-25 ZA ZA2014/03041A patent/ZA201403041B/en unknown
- 2014-06-02 IL IL232946A patent/IL232946A0/en active IP Right Grant
- 2014-12-04 HR HRP20141176AT patent/HRP20141176T1/hr unknown
- 2014-12-19 CY CY20141101072T patent/CY1116142T1/el unknown
- 2014-12-22 SM SM201400192T patent/SMT201400192B/xx unknown
-
2015
- 2015-03-23 ZA ZA2015/01986A patent/ZA201501986B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012358475A8 (en) | An inhalable medicament comprising tiotropium | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| WO2012016845A3 (en) | Pharmaceutical formulation comprising a phosphodiesterase inhibitor | |
| WO2013091775A3 (de) | Verwendung von cyclohexanolderivaten als antimikrobielle wirkstoffe | |
| PH12015500686A1 (en) | Nicotine composition | |
| MX2015010971A (es) | Derivado novedoso de pirazol. | |
| JO3091B1 (ar) | مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| WO2014205317A3 (en) | Cyclic peptides as protein targeting agents | |
| MX357619B (es) | Inhalador que comprende una composición que contiene tiotropio. | |
| CO6491065A2 (es) | Formulación farmacéutica | |
| WO2013021199A3 (en) | Eutectic mixture for pulmonary administration | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| IL229260A0 (en) | Preparations, methods and systems for respiratory administration of two or more active agents | |
| HK1221653A1 (zh) | 用於呼吸递送三种或更多种活性剂的组合物、方法和系统 | |
| MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
| WO2012110770A3 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| MX340147B (es) | Composiciones farmacéuticas y nutracéuticas del ácido abscísico. | |
| IN2014DN01619A (es) | ||
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| WO2012176138A3 (en) | Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine | |
| WO2013190497A3 (en) | Compositions and methods for treatment of inflammatory diseases of the lung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |